RTP Mobile Logo
Hematologic Oncology Update, Issue 1, 2014
Released May 2014

Featuring interviews with Drs David L Porter, S Vincent Rajkumar, Andrew M Evens and Jorge E Cortes. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.

    LEARNING OBJECTIVES

    • Develop an understanding of the biologic rationale for and early efficacy and toxicity data with the use of chimeric antigen receptor (CAR)-directed T-cell therapy and, where appropriate, facilitate patient access to ongoing trials of this investigational approach.
    • Integrate recent clinical research findings with proteasome inhibitors and immunomodulatory agents into the development of individualized induction, consolidation and maintenance treatment approaches for patients with multiple myeloma.
    • Compare and contrast the benefits and risks of approved first- and second-generation tyrosine kinase inhibitors and the protein translation inhibitor omacetaxine as therapeutic options for patients with chronic myeloid leukemia.
    • Effectively integrate the evidence-based use of novel induction and maintenance therapeutic strategies into the individualized care of patients with indolent B-cell lymphomas.
    • Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.

    ACCREDITATION STATEMENT

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains both audio and print components. The participant should review the CME information, listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial  schemas, graphics and references that supplement the audio MP3s, as well  as links to relevant full-text articles, abstracts, trial information  and other web resources.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — Dr Rajkumar had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr PorterContracted Research: Novartis Pharmaceuticals Corporation; Other Remunerated Activities: Genentech BioOncology (faculty and spouse). Dr EvensAdvisory Committee and Contracted Research: Celgene Corporation, Millennium: The Takeda Oncology Company, Seattle Genetics. Dr CortesConsulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Seattle Genetics and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    May 2014
    Expiration date:
    May 2015


    CME credit is no longer available for this issue

Acknowledge and close

Listen to audio:
Hematologic Oncology Update, Issue 1, 2014
Released May 2014

Featuring interviews with Drs David L Porter, S Vincent Rajkumar, Andrew M Evens and Jorge E Cortes. (Text and Audio Content)

Read print: